Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure
Authors:
- Arancha Martí-MartínezAMArancha Martí-Martínez
- Julio NúñezJNJulio Núñez
- Herminio López-EscribanoHLHerminio López-Escribano
- Rafael de la EspriellaRERafael de la Espriella
- Enrique SantasESEnrique Santas
- Enrique Rodriguez-BorjaEREnrique Rodriguez-Borja
- Òscar MiróÒMÒscar Miró
- Pere LlorensPLPere Llorens
- Aitor Alquézar-ArbéAAAitor Alquézar-Arbé
- Pablo Herrero-PuentePHPablo Herrero-Puente
Open Access
- 18 September 2026
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1362
Abstract
Worsening heart failure (WHF) is a complex clinical syndrome associated with a high risk of mortality and further decompensations, characterized by fluid overload and upregulated inflammatory and fibrotic processes linked to organ dysfunction. Fibroblast growth factor 23 (FGF23) is an emerging proxy of fibrosis and may interact to influence long-term outcomes in WHF patients. This study evaluated the association between FGF23 levels and long-term outcomes in patients with WHF evaluated in the emergency department (ED). A total of 635 patients from the EAHFE registry, enrolled during 2007, 2009, and 2011, were prospectively included. FGF23 was measured in the first blood sample obtained at ED presentation. During a median follow-up of 380 days (interquartile range: 126 to 456), all-cause mortality occurred in 216 patients (34.0%), while 351 patients (55.3%) experienced the composite endpoint of death/WHF ED reconsultation and 295 (46.5%) experienced death/HF hospitalization. Event rates increased progressively across FGF23 levels. Patients with FGF23 above the median (48.4 pg/mL) displayed higher rates (per 100 patient-years) of all-cause mortality (49 vs. 31, p = 0.003), death/WHF ED reconsultation (93 vs. 65, p = 0.003), and death/HF hospitalization (77 vs. 56, p = 0.043). In continuous analyses, each doubling of FGF23 remained significantly associated with an increased risk of all three outcomes after multivariable adjustment. These associations were consistent across clinically relevant subgroups, including those defined by age, sex, and kidney function, supporting the potential prognostic value of FGF23 within this cohort, although external validation is warranted.Keywords
Funding Information
- CIBER Cardiovascular (16/11/00420)
- CIBER Cardiovascular (16/11/00403)
- Unidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Institute, Spanish Clinical Research Network (PT13/0002/0031)
- Unidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Institute, Spanish Clinical Research Network (PT17/0017/0003)
- Fondo Europeo de Desarrollo Regional—Instituto de Salud Carlos III
- Sociedad Española de Cardiología
This publication has 34 references indexed in Scilit:
- Biomarkers of Hemodynamic Congestion in Heart FailureCurrent Heart Failure Reports, 2024
- Congestion and Inflammation in Heart Failure: Beyond the Chicken or the EggJournal of Cardiac Failure, 2023
- Biomarkers in heart failure: Relevance in the clinical practiceInternational Journal of Cardiology, 2022
- Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failureInternational Journal of Cardiology, 2021
- Fibroblast-Growth-Factor-23 in Heart Failure with Preserved Ejection Fraction: Relation to Exercise Capacity and OutcomesESC Heart Failure, 2020
- Fibroblast Growth Factor 23: A Biomarker of Fibrosis and Prognosis in Heart Failure with Preserved Ejection FractionESC Heart Failure, 2020
- Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failureInternational Journal of Cardiology, 2018
- FGF23 regulates renal sodium handling and blood pressureEMBO Molecular Medicine, 2014
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007